Aktuellt
SENASTE
Fluoguide announced top-line ph2b data for FG001: it enabled detection and removal of residual cancer tissue after initial tumour resection in 12/12 patients, and hence was positive. That said, the comparator, 5-ALA, did the same, and 6 patients in each arm had residual cancer too close to eloquent brain areas, and judged inoperable, opening for debate whether the ph3 trial should already assess FG001 in photothermal therapy, which would be a hugely positive development.
LÄS MER
